Recognizing MOGAD: Defining a distinct demyelinating disease

touchEXPERT FOCUS for touchNEUROLOGY, touchIMMUNOLOGY, touchOPHTHALMOLOGY    Dr. Eoin Flanagan shares his expert insights on myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) and how to distinguish it from other demyelinating diseases like multiple sclerosis (MS) and aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder (AQP4-positive NMOSD). As part of the interview, Dr. Flanagan describes MOGAD’s pathogenesis and explains how to achieve an early accurate diagnosis using the latest diagnostic frameworks.   The expert Dr. Eoin Flanagan, Mayo Clinic, Rochester, MN, USA   This activity is funded by an independent medical education grant from UCB. It is jointly provided by USF Health and touchIME.   This touchPODCAST is for healthcare professionals in the USA only.   For further information, please visit our websites: www.touchNEUROLOGY.com, www.touchIMMUNOLOGY.com, www.touchOPHTHALMOLOGY.com